Previous 10 | Next 10 |
Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, R...
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR...
AeroCentury ACY -46% after filing petition for Chapter 11Wave Life Sciences WVE -27% on setback for Huntington’s disease trial (updated).Trxade Group MEDS -21% on Q4 earnings release.Vinco Ventures BBIG -16% on providing update to ZASH Global Med...
Xenetic Biosciences (XBIO) has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens.Shares up nearly 13% p...
- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study will evaluate the XCART process of neoantigen identification and generation of tumor-spe...
Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen® platform technology FRAMINGHAM, MA / ACCESSWIRE / March ...
FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, annou...
Biotech Penny Stocks To Watch Right Now If one grouping of penny stocks that’ve gained attention in the markets, it has been biotech stocks. These companies focus on novel treatments and develop groundbreaking platforms addressing unmet medical needs worldwide. Obviously, cor...
PJSC Pharmsynthez is leveraging Xenetic's PolyXen® technology to improve the pharmacological properties of its Epolong product candidate pursuant to a royalty-bearing collaboration agreement Russian registration filing of Epolong, a polysialylated form of recombinant human erythr...
In addition to vaccines, it is now the turn of antibodies treatment to play a role in fighting COVID. There are also the diagnostics developers that still have an important stake in enabling recovery in intercontinental travel through rapid testing. Political challenges remain but...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...